Tremelimumab does not improve survival in advanced melanoma
NEW YORK (Reuters Health) - Patients with advanced melanoma who received tremelimumab in a phase III
trial had longer-lasting responses compared to patients who got standard chemotherapy, but no better overall
survival.
Source: Modern Medicine - Category: Journals (General) Source Type: news